Axsome adds AstraZeneca epilepsy candidate to pipeline through Avenue subsidiary acquisition
Axsome Therapeutics has wrapped its hands around an epilepsy candidate from AstraZeneca through an acquisition of Avenue Therapeutics’ subsidiary Baergic Bio, in a deal potentially worth more than $83 million.…